Search

Two genes cooperate to trigger leukemia development

Congratulations to the international group of researchers led by HemaSphere Editor-in-Chief Prof.

Read more

Myeloproliferative neoplasms better understood through scientific meeting

The EHA-SWG Scientific Meeting on Challenges in the Diagnosis and Management of Myeloproliferative Neoplasms held on October 12-14, 2017 in Budapest, Hungary received a 100% recommendation rating from attendees.

Read more

EHA remembers Tessa Holyoake

The Hague, September 2017

We received the sad news of Professor Tessa Holyoake’s passing. Tessa Holyoake was a Professor of Experimental Hematology and the Head of the Paul O'Gorman Leukemia Research Centre.

Read more

A brand new EHA website!

You may already have noticed the new EHA look & feel.  We are proud to share it with you already.  We are currently migrating all our pages and related information.

Read more

Impact of new technologies on diagnosis and treatment of anemias highlighted in scientific meeting

Hematologists from 18 countries and 4 continents learned more about the new techniques for diagnosis and treatment of anemias during the EHA-SWG Scientific Meeting on Anemias on February 2-4, 2017 in Barcelona, Spain.

Read more

EHA’s advocacy for hematology continues

The EHA Board has recently approved five position papers which formulate EHA’s key lobbying priorities:

Support for hematology research in Horizon 2020 (and future EU research funding programs)
Access to treatment for patients with blood disorders
EU collaboration to reduce the prices…

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

Read more

Announcement: The award winners of the prestigious EHA-ASH Translational Research in Hematology Training Award are selected

The winners of the TRTH 2015 Awards are:

 

Name

Nationality

Name

Nationality

Ileana Antony-Debre

French

Jean-Baptiste Micol

French

Pavan Bachireddy

American

Christopher Ott

American

Lucile Couronné

French

Carsten Riether

German

Moniek de Witte

Dutch

Anindita Roy

British

Ammon Fager

American

Melody Smith

American

Gillian Horne

British

Zuzana Tothova

Slovakian

Moonjung Jung

South Korea

Marcin Wlodarski

Polish

Jonas Samuel Jutzi

Swiss - German

Yuh-Ying Yeh

Taiwanese

Milka Koupenova-Zamor

American - Bulgarian

Sasan Zandi

Iranian

Marwan Kwok

British

Patricia Maiso

Spain

Are you interested in joining the…

Read more

Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.

 

Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.

Read more